4 years of historical data (2021–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BridgeBio Oncology Therapeutics Inc. trades at 21.8x earnings, roughly in line with its 5-year average of 22.8x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 8%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $794M | $175M | — | — | — |
| Enterprise Value | $793M | $173M | — | — | — |
| P/E Ratio → | 21.80 | 22.83 | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 0.88 | 0.93 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -78.7% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -78.7% | -78.7% | — | — | — |
| ROA | -76.3% | -76.3% | -27100.6% | -2.4% | -30.1% |
| ROIC | -64.9% | -64.9% | -350050.4% | -13.3% | — |
| ROCE | -83.3% | -83.3% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
BridgeBio Oncology Therapeutics Inc.'s current ratio of 10.40x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 10.40 | 10.40 | — | — | — |
| Quick Ratio | 10.40 | 10.40 | — | — | — |
| Cash Ratio | 9.05 | 9.05 | — | — | — |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 4.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | 4.6% | 4.4% | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $17M | $20M | $20M | $20M |
Compare BBOT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BBOTYou | $794M | 21.8 | — | — | — | — | -78.7% | -64.9% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 4 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BBOT stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonBridgeBio Oncology Therapeutics Inc.'s current P/E ratio is 21.8x. The historical average is 22.8x.
BridgeBio Oncology Therapeutics Inc.'s return on equity (ROE) is -78.7%. The historical average is -78.7%.
Based on historical data, BridgeBio Oncology Therapeutics Inc. is trading at a P/E of 21.8x. Compare with industry peers and growth rates for a complete picture.